#News for #Investors and #Media: Today we announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation for our investigational medicine for the treatment of gastrointestinal stromal tumour (GIST).
This marks a significant advancement and reinforces our commitment to people living with this rare cancer.
Learn more: gsk.to/4zrzdjN
We’re the first pharma company to achieve the @BSI_UK Kitemark for Minimized Risk of Antimicrobial Resistance at all our antibiotic manufacturing sites. This certifies that our manufacturing meets the highest standards to minimise the spread of AMR.
Find out more: gsk.to/3V4d64Y
5
8
1,160
#News for #investors and #media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer.
Learn more: gsk.to/4iQ3zYg
5
8
1,922
#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) has recommended a new variation for one of our vaccines.
Read more: gsk.to/48WRV81
#News for #investors and #media: We’re proud to rank 2nd overall in the Access to Medicines Index, reflecting our ongoing commitment to ensuring vital medicines and vaccines reach people who need them: gsk.to/4zF8ph2
#ATMIndex10
#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
🔗 Find out more: gsk.to/3Uct1hi
3
8
1,954
News for #Investors and #Media
Watch our CEO, Luke Miels, as he delivers news of our strong Q3 performance and continued momentum ⤵️
Find out more: gsk.to/4zggYib
#GSKResults #Earnings
#Investors and #Media: Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures in our Q3 2026 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. gsk.to/3U65izg $GSK
2
749
#News for #investors and #media:
Today, our licensor Hansoh Pharma presented new Phase 3 data in osteosarcoma, building on ongoing research efforts for patients with difficult-to-treat solid tumours. #ESMO2026
Learn more: gsk.to/3TZ5Yq9
#News for #Investors and #Media: Today, we presented data from one of our immunotherapies used to treat people living with colorectal cancer.
Read more: gsk.to/3VTGgUy
#ESMO2026
#News for #Investors and #Media: Today, we presented longer-term late-breaking data, marking encouraging progress for people living with ovarian cancer. #ESMO2026
Learn more: gsk.to/3Uh1bAd
#News for #investors & #media: Today marks an important milestone in chronic hepatitis B (CHB), with the U.S. FDA approving a new therapy for people living with the disease.
This approval reflects years of research and a continued commitment to advancing innovation in liver disease, where significant unmet need remains.
Learn more: gsk.to/4Bisj2s
#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4iwAy2D
3
1,670
#News for #Investors and #Media: Today, we shared the first data for our investigational treatment for extensive-stage small-cell lung cancer in a global population.
Learn more: gsk.to/4z38aw4
#ESMO2026
#News for #Investors and #Media: At ESMO 2026, we're showcasing over 20 abstracts from our oncology portfolio and pipeline, underscoring our expansion into solid tumours like lung, gynaecological, gastrointestinal, and GIST.
Read more:gsk.to/4dCmnr6
#ESMO2026
Dementia is one of the greatest health challenges facing society today. We're proud to support The BARBARA Alliance in a major new partnership, announced today by UK Government, bringing together academia, charities and industry to help accelerate research.
Read more here: gsk.to/4doDhJG
#News for #Investors and #Media:
Today our specialist HIV company, @ViiVHC, announced phase III study results in #HIV evaluating a long-acting option versus daily oral therapy.
Our mission: to leave no person living with HIV behind.
👉 Find out more: gsk.to/3VpWIM1
#News for #investors and #media: We have entered a licence agreement with Chimagen Biosciences for an investigational T-cell engager for multiple myeloma, advancing our leadership ambitions in blood cancer.
Find out more: gsk.com/en-gb/media/press-re…




